Progression of diabetic nephropathy appears directly related to renal tubulointerstitial injury, but the involved genes are incompletely delineated. To identify such genes, DNA microarray analysis was performed with RNA from renal proximal tubules (RPTs) of streptozotocin-induced diabetic Wistar rats, spontaneously diabetic BioBreeding rats, and rat immortalized renal proximal tubular cells (IRPTCs) exposed to high glucose (25 mM) medium for 2 weeks. Osteopontin (OPN) mRNA expression was quantified by real time-quantitative polymerase chain reaction (RT-qPCR) or conventional reverse transcriptase-polymerase chain reaction (RT-PCR). OPN mRNA expression was upregulated (5-70-fold increase) in diabetic rat RPTs and in IRPTCs chronically exposed to high glucose compared to control RPTs and IRPTCs. High glucose, angiotensin II, phorbol 12-myristate 13-acetate and transforming growth factor-beta 1 (TGF-b 1 ) stimulated OPN mRNA expression in IRPTCs in a dose-and time-dependent manner. This effect was inhibited by tiron, taurine, diphenylene iodinium, losartan, perindopril, calphostin C, or LY 379196 but not PD123319. IRPTCs overexpressing dominant-negative protein kinase C-beta 1 (PKC-b 1 ) cDNA or antisense TGF-b 1 cDNA prevented the high glucose effect on OPN mRNA expression. We concluded that high glucose-mediated increases in OPN gene expression in diabetic rat RPTs and IRPTCs are mediated, at least in part, via reactive oxygen species generation, intrarenal rennin-angiotensin system activation, TGF-b 1 expression, and PKC-b 1 signaling.
Progression of diabetic nephropathy appears directly related to renal tubulointerstitial injury, but the involved genes are incompletely delineated. To identify such genes, DNA microarray analysis was performed with RNA from renal proximal tubules (RPTs) of streptozotocin-induced diabetic Wistar rats, spontaneously diabetic BioBreeding rats, and rat immortalized renal proximal tubular cells (IRPTCs) exposed to high glucose (25 mM) medium for 2 weeks. Osteopontin (OPN) mRNA expression was quantified by real time-quantitative polymerase chain reaction (RT-qPCR) or conventional reverse transcriptase-polymerase chain reaction (RT-PCR). OPN mRNA expression was upregulated (5-70-fold increase) in diabetic rat RPTs and in IRPTCs chronically exposed to high glucose compared to control RPTs and IRPTCs. High glucose, angiotensin II, phorbol 12-myristate 13-acetate and transforming growth factor-beta 1 (TGF-b 1 ) stimulated OPN mRNA expression in IRPTCs in a dose-and time-dependent manner. This effect was inhibited by tiron, taurine, diphenylene iodinium, losartan, perindopril, calphostin C, or LY 379196 but not PD123319. IRPTCs overexpressing dominant-negative protein kinase C-beta 1 (PKC-b 1 ) cDNA or antisense TGF-b 1 cDNA prevented the high glucose effect on OPN mRNA expression. We concluded that high glucose-mediated increases in OPN gene expression in diabetic rat RPTs and IRPTCs are mediated, at least in part, via reactive oxygen species generation, intrarenal rennin-angiotensin system activation, TGF-b 1 expression, and PKC-b 1 Renal proximal tubules (RPTs) play a role in tubulointerstitial fibrosis has been addressed recently. [1] [2] [3] A number of cytokine systems such as insulin-like growth factor-1, 4 epidermal growth factor, 5 endothelin-1, 6 transforming growth factor-beta 1 (TGF-b 1 ), 7 and angiotensin II (Ang II) 8 have been implicated in tubulointerstitial injury. Renin-angiotensin system (RAS) blockade and neutralizing anti-TGF-b 1 antibodies ameliorate renal hypertrophy and suppress matrix protein mRNA expression in murine RPTs, 9, 10 indicating the importance of these factors in the progression of diabetic nephropathy.
Gene profiling studies concerning the development of diabetic nephropathy [11] [12] [13] [14] [15] [16] have identified osteopontin (OPN), as a candidate upregulated in experimental diabetic glomerular disease. In the kidneys, OPN is normally expressed in the descending thin limb of the loop of Henle and collecting ducts of the medulla but is absent from renal cortical tubules. 17, 18 OPN expression is, however, elevated in established experimental models such as diabetic nephropathy in the rat, 19, 20 models with unilateral ureteral obstruction, 21, 22 and renal disease associated with cortical tubulointerstitial fibrosis. 23, 24 Such observations, together with the apparent role of OPN in inflammation and cell reruitment, suggest that OPN may play a role in the evolution of diabetic nephropathy. 25 We performed DNA microarray profiling to identify genes uniquely upregulated within diabetic rat RPTs. We observed that OPN was upregulated both in diabetic rat RPTs and in immortalized renal proximal tubular cells (IRPTCs) chronically exposed to high glucose. We then demonstrated that the high glucose effect on OPN gene expression in IRPTCs is mediated, at least in part, via reactive oxygen species (ROS) generation, RAS activation, protein kinase C-beta 1 (PKC-b 1 ) signaling, and TGF-b 1 gene expression. Table 1 showed the physical data. Weight gain was significantly lower after 2 weeks (day 14) of diabetes but was improved with insulin treatment. Animals in both diabetic groups had elevated blood glucose and a higher ratio of kidney weight/body weight as compared to non-diabetic group. Normalization of blood glucose by insulin reversed the ratio of kidney weight/body weight to non-diabetic levels.
RESULTS
Gene expression profiling in diabetic renal proximal tubular cells RAE230A expression chips analyzed the changes in mRNA levels of 15 925 genes and expressed sequence tags (ESTs). The percentage of these genes present in RPTs isolated from non-diabetic BioBreeding (BB) rats, Wistar rats, and control IRPTCs were 58.7, 57.8, and 28.9%, respectively. ESTs were excluded in the analysis.
In RPTs isolated from diabetic BB rats, streptozotocin (STZ)-induced diabetic Wistar rats, and high glucose-treated IRPTCs, 144, 60, and 21 genes were upregulated, respectively (Figure 1a ), while 83, 37, and 13 genes were downregulated, respectively ( Figure 1b ).
Only two genes, OPN and CCAAT enhancer binding protein-delta (C/EBP-d), were commonly upregulated in RPTs from diabetic BB rats, STZ-induced diabetic Wistar rats, and high glucose-treated IRPTCs ( Table 2) . Tables 3 and   Table 1 4 identify the genes that most often increased or decreased in RPTs from diabetic BB rats and STZ-induced diabetic Wistar rats, respectively, with or without insulin treatment.
Validation of OPN mRNA expression in diabetic RPTs by real time-quantitative polymerase chain reaction (RT-qPCR)
We used a specific RT-qPCR for rat OPN mRNA to validate DNA microarray findings. Figure 2a , b, and c illustrate the results of OPN mRNA expression in freshly isolated RPTs from Wistar rats, BB rats, and IRPTCs, respectively. In Wistar rats with STZ-induced diabetes, OPN mRNA expression was increased approximately 70-fold (Po0.001) (n ¼ 14) as compared to the controls. This increment was reversed by insulin treatment (Po0.001; n ¼ 14). In BB rats, OPN mRNA expression was elevated greater than fivefold in the diabetic group as compared to the non-diabetic controls (Po0.001; n ¼ 10). Insulin treatment prevented the increase of OPN mRNA in diabetic BB rats. The basal expression of OPN mRNA in non-diabetic BB rats, however, was twofold higher as compared to non-diabetic Wistar rats (Po0.01) (data not shown). Prolonged exposure of IRPTCs to high glucose (i.e., 25 mM) for 2 weeks also induced a fivefold increase (Po0.001) in OPN mRNA expression compared to controls incubated in normal glucose (5 mM) (n ¼ 9). Insulin (10 À7 M) also reversed the high glucose effect on OPN mRNA expression in IRPTCs (Po0.001; n ¼ 9).
Effect of high glucose on OPN mRNA expression in IRPTCs
Quantification by conventional reverse transcription-polymerase chain reaction (RT-PCR) revealed that 25 mM D-glucose stimulates OPN mRNA expression in IRPTCs in a time-dependent manner ( Figure 3a) . A significant increase of OPN mRNA expression (X2-fold) was observed after 24-h incubation and rose progressively thereafter. In contrast, 25 mM D-mannitol had no significant effect, indicating that upregulation of OPN gene expression is not due to increased osmolarity ( Figure 3b ). Conventional RT-PCR for OPN mRNA was subsequently used in all experiments.
Signaling mechanism of high glucose regulation of OPN mRNA expression
To elucidate the underlying pathway of high glucose regulation of OPN gene expression in IRPTCs, inhibitors of several signaling pathways were tested. As illustrated in Figure 4a , diphenylene iodinium (DPI) (1 Â 10 À6 M), tiron (1 Â 10 À4 M), taurine (1 Â 10 À3 M), and Mn (III) tetrakis (4-benzoic acid) porphyrin chloride (MnTBAP) (8 Â 10 À5 M) blocked the effects of high glucose on OPN mRNA expression. These results indicate that ROS generation might mediate, at least in part, the high glucose effect on OPN mRNA expression. Furthermore, high glucose effect on OPN mRNA expression was inhibited in the presence of losartan (1 Â 10 À6 M), perindopril (1 Â 10 À5 M), calphostin C (1 Â 10 À7 M), and LY 379196 (1 Â 10 À7 M), but not in the presence of PD123319 (an AT 2 R blocker) (1 Â 10 À5 M) ( Figure 4b ). These results suggest that upregulation of OPN gene expression by high glucose might be mediated, at least in part, by intrarenal RAS activation and PKC signaling.
Effect of Ang II on OPN mRNA expression in IRPTCs
Figure 5a reveals that Ang II stimulated OPN mRNA expression in IRPTCs with an optimal effect at 10 À9 M. The stimulatory effect of Ang II was inhibited in the presence of Figure 5b ). These data indicate that the Ang II effect on OPN mRNA expression is mediated via AT 1 receptor (AT 1 R) activation, ROS generation, and PKC signaling but not AT 2 receptor (AT 2 R).
PKC-b signaling and OPN mRNA expression in IRPTCs
To confirm the role of PKC signaling in OPN mRNA expression, phorbol 12-myristate 13-acetate (PMA) was added to the culture media. Figure 6a illustrates that PMA stimulated OPN mRNA expression in a dose-dependent manner (i.e., 10 À10 -10 À8 M). The addition of calphostin C and LY 379196 (a PKC-b inhibitor) reversed the PMA action on OPN mRNA expression ( Figure 6b ), demonstrating that the PKC-b signaling pathway is important in regulating OPN mRNA expression in IRPTCs. (Figure 8a ). In addition, TGF-b 1 had no effect on OPN mRNA expression in IRPTCs stably transfected with dominant-negative PKC-b 1 (Figure 8a ). Furthermore, IRPTCs stably transfected with sense TGF-b 1 displayed significantly higher basal OPN mRNA expression compared to control cells (Po0.005), and high glucose further enhanced OPN mRNA expression in these cells (Figure 8b) . In contrast, cells stably transfected with antisense TGF-b 1 exhibited significantly lower OPN mRNA expression compared to the controls (Po0.01) and did not respond to high glucose stimulation (Figure 8b ).
PKC-b 1 mediates high glucose, TGF-b 1 , and Ang II effect on OPN mRNA Expression Figure 9a indicates that high glucose, TGF-b 1 , and Ang II stimulated OPN mRNA expression but was abolished in IRPTCs that were stably transfected with dominant-negative (DN) PKC-b 1 . High glucose, TGF-b 1 ,and Ang II also stimulated PKC-b 1 phosphorylation in IRPTCs (Figure 9b ). Similarly, the stimulatory effect of high glucose, TGF-b 1 , and Ang II on PKCb 1 phosphorylation was also inhibited in DN PKC-b 1 stable clones. These data confirm that PKC-b 1 may mediate, at least in part, the stimulatory effect of high glucose, TGF-b 1 , and Ang II action on OPN mRNA expression ( Figure 10 ).
DISCUSSION
Among 227 and 97 differentially expressed transcripts in RPTs from respective spontaneously diabetic BB rats and STZ-induced diabetic Wistar rats, only 43 were commonly expressed in RPTs of both experimental diabetes models (19% in BB rat RPTs, 44% in STZ-induced diabetic Wistar rat RPTs). OPN is one of two genes (CCAAT enhancer-binding protein-d was the other) that is differentially upregulated in diabetic rat RPTs and in IRPTCs chronically exposed to high glucose. RT-qPCR confirmed this observation. OPN mRNA expression levels in diabetic rat RPTs and in IRPTCs chronically exposed to a high glucose milieu were 5-70-fold higher than in control RPTs and IRPTCs. Insulin treatment normalized OPN mRNA expression. These data are in agreement with findings that OPN expression is enhanced in the renal cortex and in mesangial cells of STZ-induced diabetic rat kidneys 20, 26 and in human diabetic RPTCs. 27, 28 Surprisingly, no apparent common gene (in comparison to diabetic rat RPTs) appeared to be downregulated by insulin in IRPTCs. While no explanation for this observation is evident, one possible explanation based on our gene chip studies, however, might be that a smaller percentage of genes is expressed in IRPTC as compared to diabetic rat RPTs, that is, 28.9% in IRPTCs versus 58.7 and 57.8% in non-diabetic BB rats and Wistar rats, respectively.
High levels of D-glucose upregulated OPN mRNA expression in a time-and dose-dependent manner. This stimulatory effect of high glucose on OPN mRNA expression was inhibited in the presence of DPI, tiron, taurine, MnTBAP, losartan, perindopril, calphostin C, and LY 379196, suggesting that the high glucose effect on OPN expression might be mediated, at least in part, via ROS generation, RAS activation, and PKC-b signaling. At present, the exact molecular linkage of high glucose and ROS on OPN expression is incompletely delineated. One possibility may be that high glucose evokes mitochondrial ROS generation with inhibition of glyceraldehyde-3-phosphate dehydrogenase activity and flux of glucose to the tricarboxylic acid cycle but stimulates the de novo synthesis of diacylglycerol (the polyol pathway) and subsequently activates PKC-b. 29, 30 This possibility is supported by our earlier work that high glucose evokes ROS generation and activates the polyol/PKC pathway with the outcome being angiotensinogen gene expression and intrarenal RAS activation in IRPTCs. 31, 32 Losartan and perindopril but not PD123319 prevented the stimulatory effect of high glucose on OPN mRNA expression. Ang II stimulated OPN mRNA expression in IRPTCs, and its effect was inhibited in the presence of losartan, calphostin C, LY 379196, tiron, or DPI but not in the presence of PD123319 and perindopril. These results further demonstrate that the stimulatory action of high glucose and Ang II on OPN mRNA expression is mediated via AT 1 R activation of nicotinamide adenine dinucleotide phosphate (reduced form) oxidase evoking ROS generation and consequently PKC-b 1 activation in IRPTCs. These findings are similar to others in that Ang II stimulated OPN expression in adult rat ventricular myocytes and cardiac microvascular endothelial cells, and these effects were blocked by DPI. 33 Moreover, our results are supported by the studies of Li et al. 20 that longterm treatment with ramipril attenuates OPN expression in diabetic rat kidneys.
We tested PMA, a universal PKC activator to confirm PKC signaling. Our results showed that PMA stimulated OPN mRNA expression, and that its action was inhibited in the presence of calphostin C and LY 379196. These data confirm that PKC-b plays an important role in modulating OPN expression in IRPTCs and support studies by others disclosing that PKC signaling modulates OPN gene expression in different cell types [34] [35] [36] and in tubular epithelial cells of STZ-induced advanced experimental diabetic nephropathy. 37 TGF-b 1 is a potent stimulus of OPN transcription and protein expression in cultured rat renal epithelial cell line. 38 Our data confirm that TGF-b 1 upregulates OPN mRNA expression, and its effect is inhibited in the presence of PKC-b inhibitors as well as in IRPTCs stably transfected with DN PKC-b 1 cDNA. Furthermore, IRPTCs stably transfected with sense TGF-b 1 cDNA displayed a higher basal level of OPN mRNA, and high glucose further enhanced OPN mRNA expression. In contrast, stable transfection of IRPTCs with antisense TGF-b 1 completely abolished the high glucose effect on OPN mRNA expression. Stable transfection of IRPTCs with DN PKC-b 1 also attenuated the stimulatory effect of high glucose, Ang II, and TGF-b 1 on OPN mRNA expression and PKC-b 1 phosphorylation in IRPTCs. Our report that PKC-b 1 mediates the stimulatory effect of high glucose, Ang II, and TGF-b 1 on OPN gene expression in RPTCs is novel. There is evidence that activation of PKC-e and/or PKC-d can augment OPN mRNA expression in skin cancer cells (JB6). 34 Studies are ongoing to examine the effect of other PKC isoform(s).
In summary, we have identified several novel transcripts using DNA microarray profiling, subsequently confirmed with RT-qPCR, that might be potential candidates to predict the risk of developing diabetic nephropathy. Our data suggest that ROS generation, intrarenal RAS and TGF-b 1 gene expression, and PKC-b 1 activation may mediate, at least in part, the high glucose effect on upregulation of OPN gene expression in the diabetic kidney, ultimately leading to tubulointerstitial fibrosis and end stage renal disease. We would propose the following molecular pathway for high glucose action on OPN gene expression in IRPTCs: First, high glucose evokes ROS generation, and the resultant ROS stimulate angiotensinogen gene expression and intrarenal Ang II formation via different signaling pathways, including PKC-b 1 . Subsequently, Ang II interacts with AT 1 R to activate PKC-b 1 signaling and also stimulate nicotinamide adenine dinucleotide phosphate (reduced form) oxidase to evoke ROS generation, which subsequently leads to further enhancement of PKC-b 1 activation. Ang II also stimulates TGF-b 1 gene expression and further augments PKC-b 1 activation in IRPTCs. Finally, PKC-b 1 stimulates OPN expression in the diabetic kidney, potentially leading to tubulointerstitial fibrosis and end stage renal disease. La Roche Biochemicals (Laval, QC, Canada). Anti-PKC-b 1 and antiphospho-PKC-b 1 (T642) antibodies were purchased from Abcam Ltd., Cambridge, UK.
MATERIALS AND METHODS Chemicals and constructs
The expression vector pcDNA 3.1 containing the dominantnegative(DN) PKC-b 1 cDNA with critical lysine in the ATP-binding domains mutated to methionine was a gift from RV Farese (University of South Florida, Tampa, FL, USA). 39 We cloned a full-length rat TGF-b1 cDNA from IRPTCs using conventional RT-PCR. Sense and antisense primers corresponding to nucleotides N þ 401 to N þ 424 (5 0 -GCC GCC TCC CCC ATG CCG CCC TCG-3 0 ) and N þ 1585 to N þ 1565 (5 0 -TCA GCT GCA CTT GCA GGA GCG-3 0 ) of rat TGF-b 1 cDNA 40 were used in RT-PCR. The rat TGF-b 1 cDNA with NotI restriction enzyme site attached at both 5 0 and 3 0 termini was subsequently subcloned into the NotI site of the expression vector pcDNA 3.1 (InVitrogen, Inc.) in sense and antisense orientation.
Animals
Two animal models of insulin-dependent diabetes (type I) were employed: spontaneously diabetic BB rats and STZ-induced diabetic Wistar rats. [41] [42] [43] [44] [45] Adult (60-day old) male BB rats were purchased from Health Canada (Ottawa, ON, Canada), acclimatized for 2 days, and blood sugar levels were measured every other day (Accu-Check Compact, Roche Diagnostics, Laval, QC, Canada). BB rats with blood glucose 425 mM were divided into two groups: untreated diabetic (n ¼ 4) and insulin-treated diabetic rats (n ¼ 4, treated with subcutaneous insulin implant, Linplant (Linshin, Scarborough, ON, Canada) to maintain euglycemia). After 2 weeks of diabetes, the BB rats were killed and kidneys were removed immediately for proximal tubule isolation. Non-diabetic BB rats of the same age but without diabetes served as controls (n ¼ 4). This protocol was replicated three times, total n ¼ 12 per category.
All animals were allowed free access to rat chow and water. All methods of animal care and killing were approved by the Animal Care Committee of the Centre hospitalier de l'Université de Montréal (CHUM).
Isolation of rat RPTs
At 2 weeks after diabetes was induced, the rats were anesthetized and killed by decapitation at the same time point for each group. Proximal tubule isolation was performed immediately by Percoll gradient 46 with slight modifications as described previously. 45 Cell culture IRPTCs (Cell line #93-p-2-1 at passages 13-18) were employed. 47 The culture conditions of IRPTCs have been described previously. 48 IRPTCs were stably transfected with DNA using Lipofectamine reagent (InVitrogen, Inc.) as previously described. 48 For DNA microarray analysis, IRPTCs were grown for 2 weeks in either 5 mM D-glucose plus 20 mM D-mannitol DMEM or 25 mM D-glucose DMEM in the absence or presence of insulin (10 À6 M) mimicking the diabetic milieu. Then, total RNA was harvested for DNA chip microarray analysis.
RNA extraction
Total RNA was extracted with Trizol reagent according to the protocol of the supplier (InVitrogen, Inc.). Prior to DNA microarray analysis, an additional cleanup step was used by employing an RNeasy Mini Kit (QIAGEN Inc., Valencia, CA, USA).
DNA microarray analysis
Total RNAs from four individual rats in each group or four cell culture dishes per treatment group were pooled and then reversetranscribed into cDNA, which, in turn, was used as a template for the generation of biotin-labeled cRNA (Enzo kit, Affymetrix, Santa Clara, CA, USA). The cRNA was fragmented and hybridized to Affymetrix GeneChip RAE230A (Affymetrix) at the DNA Microarray Core Facility of the CHUM. The hybridized chips were stained with streptavidin-phycoerythrin conjugate (InVitrogen, Inc.) and then scanned by Agilent GeneArray 2500 Scanner (Affymetrix). Quantitative analysis of hybridization patterns and intensities was performed automatically by Affymetrix software, and the resulting data were analyzed by Affymetrix Microarray Suite Version 5.0 software. Each GeneChip was evaluated by 'single array analysis' as described by Affymetrix. The 'fold change' in gene expression between the control and the diabetic groups was calculated by signal log ratio and formulae were provided by Affymetrix.
RT-qPCR
Total RNA isolated from individual rat RPTs or IRPTCs was used for RT-qPCR assay to quantify OPN and b-actin mRNA expression. Briefly, 4 g of total RNA was used to synthesize first-strand cDNAs by employing the Super-Script pre-amplification system (InVitrogen, Inc.). Then, the first-strand cDNA was used for RT-qPCR using QuantiTect TM SYBR Green PCR Kit (Qiagen Inc., Valencia, CA, USA) and Rotor-Gene TM 3000 (Montreal Biotech., Montreal, QC, CA) according to the manufacturer's protocol. PCR reactions in triplicate underwent 44 cycles of 951C for 15 s, 601C for 15 s, and 721C for 30 s. After 44 cycles of amplification, PCRs were further extended at 721C for 7 min. The parameter C t (threshold cycle) value was measured to determine starting copy number of target genes using the standard curve. Lower C t value indicates higher amount of PCR products. The primers for OPN (AB001382.1) and b-actin (NM_007393) are the following: sense OPN: 5 0 -GCT CTC AAG GTC ATC CCA GTT G-3 0 (N-556 to N-577 bp) and antisense OPN: 5 0 -TGT TTC CAC GCT TGG TTC ACT-3 0 (N-666 to N-646 bp); sense b-actin: 5 0 -CGT GCG TGA CAT CAA AGA GAA-3 0 (N-704 to N-724 bp) and antisense b-actin: GCT CGT TGC CAA TAG TGA TGA (N-840 to N-820 bp).
Conventional RT-PCR
Conventional RT-PCR was used to amplify rat OPN and b-actin cDNA fragments with the PCR core kit according to the supplier's instructions (InVitrogen, Inc.). After denaturation at 941C for 3 min, OPN or b-actin cDNA was amplified as follows: 941C for 20 s, 601C for 20 s, and 721C for 40 s. After 25 cycles of amplification, PCRs were further extended at 721C for 5 min.
The sense and antisense rat OPN primers were 5 0 -CTG GCA GTG GTT TGC CTT TGC C-3 0 and 5 0 -CGT CAG ATT CAT CCG AGT TCA C-3 0 , corresponding to the nucleotide sequences N þ 86 to N þ 100 and N þ 389 to N þ 410 of rat OPN cDNA, 49 respectively. The sense and antisense rat b-actin primers were 5 0 -ATG CCA TCC TGC GTC TGG ACC TGG C-3 0 and 5 0 -AGC ATT TGC GGT GCA CGA TGG AGG G-3 0 , corresponding to the nucleotide sequences N þ 155 to N þ 179 of exon 3, and nucleotide sequences of N þ 115 to N þ 139 of exon 5 of the rat b-actin gene, 50 respectively.
The digoxigenin method was used for detection with the digoxigenin-labeled oligonucleotide 5 0 -CAG ATG CTG TAG CCA CTT GGC TGA AGC-3 0 , corresponding to nucleotide N þ 189 to N þ 215 of rat OPN cDNA. 49 After OPN mRNA analysis, the same membrane was stripped and rehybridized with a b-actin oligonucleotide probe (sequence: 5 0 -TCC TGT GGC ATC CAT GAA ACT ACA TTC-3 0 , corresponding to nucleotides N þ 9 to N þ 35 of exon 4 of the rat b-actin gene. 50 OPN mRNA levels were normalized by corresponding b-actin mRNA levels.
Effect of high glucose, TGF-b 1 , and Ang II on PKC-b 1 activation in IRPTCs The effects of high glucose, TGF-b 1 , and Ang II on PKC-b 1 activation in IRPTCs were assessed by Western blotting of phosphorylated PKC-b 1 . Briefly, IRPTCs and IRPTCs stable transfected with DN PKC-b 1 plasmid were synchronized overnight and then incubated for 24 h in 5 mM D-glucose DMEM medium plus 20 mM D-mannitol in the absence or presence of 2 ng/ml TGF-b 1 or 10 Â 10 À9 M Ang II, or incubated in 25 mM D-glucose medium. Western blotting was performed as described previously. 51 The membrane was initially blotted for phosphorylated PKC-b 1 (T642) antibody and then re-blotted for total PKC-b 1 antibody.
Data and statistical analysis
Microarray data obtained from Affymetrix Microarray Suite Version 5.0 software were imported into Microsoft Excel 2000 for analysis. All other calculations were performed by GraphPAD Prism Version 3.02 software. Three to four separate experiments were conducted per protocol, and each treatment group was assayed in duplicate. The data are expressed as mean7s.d. Statistical significance between the groups was determined by one-way analysis of variance followed by the Bonferroni test. A probability level of Po0.05 was considered statistically significant.
